A retroviral vector (BAG) was used to transfer human prostaglandin H synthase (PGHS-1) gene into a human endothelial cell line for enhancement of PGI2 synthesis. Cells infected with BAG containing PGHS-1 cDNA in the sense orientation relative to the retroviral promoter (PGHS(S)) expressed a 30-fold increase in mRNA but, due to a reading frame shift, did not show an increase in PGHS protein or in PGI2 synthesis, while those with PGHS-1 in reverse orientation relative to the viral promoter (PGHS(R)), produced a > 10-fold increase in PGHS mRNA over the control (169±22 vs 14.8±1.2 amol/gg RNA) with a concordant increase in PGHS protein (5.82±1.07 vs 0.23±0.04 ng/mg protein) and enzyme activity. Primer extension analysis of PGHS(R) revealed two transcription start sites located in the SV40 late promoter region adjacent to PGHS-1 cDNA. PGHS(R) cells produced a high basal PCI2 level which was increased by several-fold in response to stimulation by ionophore, arachidonic acid, and thrombin. Kinetic analysis revealed the PCI2 synthetic rate to be 14 ng/min-' per million cells and t12 of PCI2 synthesis, 13.3 min. These findings indicate that transfer of PGHS-1 gene into vascular cells enhances PCI2 synthesis and may be a useful strategy for restoring thromboprotective property of damaged blood vessels. (J.
of biologically important prostanoids, i.e., prostacyclin (PGI2), thromboxane A2, PGE2, PGD2, and PGF2,. PGHS is distributed in most mammalian tissues in low abundance. It is autoinactivated during catalysis (4, 5) which severely curtailed the prostanoid synthesis. At least two forms of PGHS have been identified and their genes have been cloned. PGHS originally cloned from ram seminal vesicles (designated PGHS-1 ) and subsequently from mouse tissues, human endothelial cells, and platelets, is well conserved and considered to be constitutive (6) (7) (8) (9) (10) while the second type of PGHS (PGHS-2) cloned from chicken embryonic fibroblasts and mouse 3T3 fibroblasts is highly inducible ( 1-1 3).
Cultured human endothelial cells have been used as a cell model for studying the regulation of PGHS expression and the relation of PGHS level to PGI2 biosynthesis. Several laboratories including ours have shown that the extent of PGI2 biosynthesis is governed by the level ofPGHS-1 which depends on the balance between de novo synthesis and autoinactivation of PGHS (14) (15) (16) (17) . However, the exact relationship between PGHS expression and the capacity for PGI2 synthesis has not been established by quantitative analysis because of technical limitations for measuring low levels of PGHS mRNA and protein. In this study, we used retrovirus-mediated transfer of PGHS-I cDNA to enhance PGHS expression in an endothelial cell line EA.hy926. The PGHS mRNA level in infected cells was enhanced over that in uninfected cells by one to two orders of magnitude with a concordant increase in PGHS protein level and enzyme activity. These cells produced a large quantity ofPGI2 in response to arachidonic acid, calcium ionophore A23 187, and thrombin stimulation. The rate of PGI2 synthesis was determined to be 14 ng/min-' per million cells and t/2 of PGI2 synthesis was 13.3 min.
Methods
Retroviral vectors. The BAG vector, kindly supplied by Connie Cepko, Harvard Medical School, was constructed as previously described (18) . It contains a 3-kb BamHI fragment encoding Escherichia coli ,8-galactosidase gene (Fig. 1 ). To prepare retroviral vectors for PGHS gene transfer, the j#-gal fragment was replaced with a 2.5-kb BamHI fragment which includes the entire coding region and the polyadenylation signal of a human endothelial cell PGHS-I cDNA cloned in our laboratory. When Northern blot analysis. RNA was prepared from infected and uninfected cells by a procedure previously described (23) . Poly A( +) RNA was prepared from the total RNA by oligo-dT column chromatography. Gel electrophoresis, gel transfer, and hybridization with a 2.1-kb human PGHS cDNA were performed as previously described (23) .
Quantitative PCR. This assay was based on procedures previously described (24) (25) (26) . For assay of PGHS-I mRNA, we used a fragment of human PGH synthase genomic DNA (gDNA) as the template for generating gRNA to serve as an internal standard. This template was 320 bp in size, covering all of exon 6, a small fragment of exon 7, and the l O-bp sequence between exons 6 and 7. The sequences of 5'-and 3'-flanking oligonucleotide primers used for PCR amplification were: 5'-GGAAGAAGCAGTTGCCAGATGCCCAGCTCC-3' (designated W-16) and 5'-TTGTCTCCATAAATGTGGCCGAGGTCTACC-3' (designated W-17). Both primers were synthesized by Genosys Biotech, Houston, Texas. The detailed assay procedure was identical to that already described (26) .
Primer extension analysis. The transcription initiation sites of PGHS(R) constructs were determined by primer extension using two synthetic antisense oligonucleotide primers: (a) a 24-mer (5'-CAA-CAGGGATTCACTGGCGTGGGC-3'), the 5'-terminus of which is corresponding to the nucleotide residue 110 downstream from the ATG site of PGHS cDNA (designated W-1) and (b) a 20-mer (5'-AGGAGCGGAATTCCCAGCAA-3', designated W-76) the 5'-terminus of which is corresponding to the residue 54 downstream from the ATG site. Total cellular RNA (120 Mg) isolated from PGHS(R) cells was used as the template for primer extension which was performed according to the procedure described (27) . Using W-l as the primer, we observed a single band of258 nucleotides in length and with W-76 as the primer, we noted a major band of278 and a minor band of 198 nucleotides in length.
Prostacyclin synthesis. Monolayers ofcells were washed twice with culture medium and were incubated with various stimulants for 1 h at 370C before the supernatant liquid was removed and assayed for 6KPGFI. by specific radioimmunoassay as described previously (28) . .:
Sep-Pak cartridge (Waters Associates, Millipore Corp., Milford, MA) as described by Eling et al. (29) . Recovery ofeicosanoids in this extraction procedure was -95%. Eicosanoids were separated and analyzed by reverse-phase HPLC as previously described (30) . Enzyme immunoassay for PGHS protein levels. The assay used polystyrene beads (3.2 mm in diameter; Precision Plastic Ball Co., Chicago, IL) coated with rabbit polyclonal anti-PGHS antibody or preimmune IgG. Monolayers of cultured cells were lysed and the protein was solubilized with 1% n-octyl ,8D-glucopyranoside. Samples and standards were incubated with the antibody-coated polystyrene beads for 3 h at room temperature and then overnight at 4VC. The beads were washed and then incubated at room temperature for 4 h with anti-PGHS F(ab)'2 fragment conjugated to jD-galactosidase. After washing, a fluorescent substrate (4-methyl umbelliferyl l-D-galactoside) was added and incubation continued for 90 min. The reaction was stopped and the fluorescence intensity (X ex = 360 nm; X em = 450 nm) was determined. A calibration curve derived from ovine PGHS standards was plotted on a logarithmic scale and a least-squares fit determined by linear regression. The correlation coefficient was > 0. 995 (Fig. 2 A) . The mRNA levels were quantified by competitive PCR assay (Fig. 2, B and C) (Fig. 3 a) . significantly higher than that present in uninfected cells (Fig. 3  b) . On the other hand, the enzyme level expressed in PGHS(R) cells was -25-fold higher than that in the control cells. These results were supported by HPLC data shown in Fig.  4 . PGHS(S) cells produced very small amounts of cyclooxygenase products equivalent to those of control cells when they were treated with [ 1-4C ] AA while PGHS( R) cells generated a large quantity ofPGI2 and PGE2. The PGHS-1 enzyme activity estimated from the HPLC analysis was in accord with that of protein expression in these cells. Despite expression ofan increased PGHS-l mRNA level by the insertion of PGHS-1 cDNA into the BAG vector in a sense orientation relative to retroviral LTR promoter, expression of PGHS protein and enzyme activity were not concordantly'enhanced. This discrepancy led us to suspect that there might be a shift in the reading frame. We analyzed the nucleotide sequence of the fragment between the retroviral gag ATG originally placed in the BAG vector as the translation start codon for f3-galactosidase and the inherent start codon of PGHS cDNA inserted into the BAG in place of 0-galactosidase (Fig.   1 ). We found that PGHS ATG was 1 bp out of frame from the gag ATG. Failure of a proper protein translation because of reading frame shift may be due to the preferential use ofthe gag ATG as the translation start codon.
Judging from the length of PGHS-1 mRNA (3.3 kb) expressed in PGHS(R) cells, we postulated that the transcription initiation site was localized within the SV40 promoter region which was originally inserted in the BAG vector for promoting the expression of the neoR gene (Fig. 1) . To determine this, we carried out primer extension experiments to define the potential transcription start sites. Primer extension analysis revealed two start sites mapped to the late SV40 promoter region close to the origin of DNA replication (Fig. 1) . To define the exact transcription initiation sites, we sequenced this region with two synthetic primers, designated W-1 and W-76 (see Methods for the sequences). The sequence we obtained matched that reported in the GenBank for the SV40 late promoter region (accession number VO 1380) (Fig. 1) . Based on the length of the primer extension products, we mapped the transcription start sites to nucleotide residue 71 and residue 145.
The extent of PGI2 synthesis by PGHS(R) cells is shown in Table I . These cells produced a high basal level of PGI2 when compared to control and PGHS(S) cells. They were capable of responding to stimulation by thrombin, ionophore A23187, and AA which increased PGI2 formation by three-, eight-, and fivefold over the basal PGI2 level, respectively (Table I) . The PGI2 levels produced by PGHS(R) cells in response to stimulation were at least 20-fold higher than those produced by PGHS (S) or parental cells under an identical stimulatory condition. Multiple passages of PGHS( R) cells in culture did not have an apparent effect on their PGI2-generating capacity. Cells that had undergone seven passages in culture produced a similar quantity of PGI2 as those which were freshly infected with PGHS(R) vectors before passage (PO) ( Time, min Figure 5 . Kinetics of PGI2 synthesis in PGHS(R) cells. Each dark dot represents the mean value of two experiments. The data were fit to a one-exponential regression. Similar experiments were performed in uninfected cells. Due to low PGI2 formation, fitting ofthe curve was difficult and hence the synthetic and decay rates were impossible to determine (data not shown).
PGI synthase during catalysis (4, 5, 31 ). PGI2 synthetic rate has been difficult to quantify because of low levels of PGI2 productions. Since this stably infected endothelial cell line produced a high level of PGI2, we thought it might be suitable for accurate determination of PGI2 synthetic rate. We treated PGHS(R) cells with AA (10 uM) at 370C and at indicated time points, a small aliquot of the cultured medium was collected and its 6-keto-PGF10 content was measured by RIA. The results are shown in Fig. 5 . The time course ofPGI2 synthesis in PGHS(R) cells fits a single-exponential regression. PGI2 synthesis reached a plateau after the cells had been treated with the agonists for 30 min. The maximal production ofPGI2 obtained by nonlinear regression was 270 ng/ 106 cells and the rate constant was 0.052 min' (Fig. 5) . PGI2 synthetic rate was 14 ng/min-per 106 cells and the t112 of PGI2 synthesis was 13.3 At the end of each hourly stimulation, medium was collected and the 6-keto-PGFIa content was measured. In five experiments, the 6-keto-PGFIa content at the end of the first hour treatment was 365.5±40.5 ng/ 106 cells which declined to 85.5±12.5 ng/ 106 cells after the second AA challenge (a > 75% decline) and 39.5±9.0 ng/ 106 cells after the third AA challenge. These results confirm that PGHS-1 inactivates rapidly during catalysis and that PGI2 synthesis is still severely curtailed even in the presence of a large quantity of PGHS-1.
Discussion
Prostacyclin production is regulated at each ofthree enzymatic steps that catalyze its biosynthesis. Phospholipase A2 is considered to be the limiting step for the initial rate of prostanoid synthesis, while PGHS is thought to control the extent ofprostanoid production due to its suicidal inactivation during catalysis (4, 5, 3 1 ). Prostacyclin synthase also undergoes autoinactivation but its role in controlling PGI2 synthesis generally is less clear. Despite extensive investigations, prostanoid synthetic rate in cells has been difficult to quantify because of low abundance of PGHS. In this study, we used retrovirus-mediated transfer of PGHS-1 cDNA to enhance the expression of this enzyme by -20-fold over the basal level of enzyme expression. Unlike the use of plasmid vector for transient expression, the retrovirus-mediated transfer ofPGHS-1 cDNA into aphysiologically relevant cell is stable and is unaltered by subculture ofcells. This transduced cell line has been subcultured for more than 10 passages and the level of PGHS-1 expression as well as the capacity for PGI2 synthesis remains unchanged. Availability ofthis cell line enables us to reliably quantify PGO2 synthetic rate and t1/2 ofPGI2 synthesis. A short half-life of PGO2 synthesis (13.3 min) is due to autoinactivation of PGHS and PGI synthase. Relative contribution of each enzyme's inactivation to the short half-life of PGI2 production is unclear. Since PGHS-1 levels in this cell line are amplified by -20-fold without a concurrent increase in PGI synthase levels, it may be speculated that limited PGO2 synthesis is due mostly to inactivation of PGHS-1. This notion is supported by the progressive decline ofPGI2 synthesis by this cell line when it was repeatedly challenged with arachidonic acid. Despite a marked increase in PGHS-1 levels by retrovirus-mediated transfer of PGHS-l gene, the capacity ofPGI2 synthesis was reduced by 75% after a single AA treatment and declined at a similar rate after each subsequent AA challenge. We cannot rule out the possibility, however, that PGHS and PGO synthase may be autoinactivated at a similar rate by a similar enzyme inactivation mechanism.
Although it is generally accepted that the extent ofprostanoid synthesis is controlled by PGHS, this has not been directly documented. This study provides direct evidence to support the notion that the extent of PGO2 can be greatly enhanced by increasing the level ofPGHS-1 in the cells. We found that PGI2 production in response to physiological agonists was greatly enhanced by the transduced cell line. This is of considerable therapeutic implications. Since PGI2 is a major defense molecule protecting the vascular wall against thrombosis, loss of PG12-producing cells due to denudation of vascular endothelium has been considered as a major factor for uncontrolled thrombus formation that is responsible for acute coronary and cerebral arterial occlusion. Virus-mediated (retrovirus or adenovirus) transfer of PGHS gene represents a powerful strategy for restoring this defense mechanism in damaged vessel wall. In this cultured cell study, we clearly show that this strategy is feasible. Work is now in progress to determine the feasibility of transferring PGHS by retroviral or adenoviral vectors in vivo in animal models.
Analysis by HPLC of metabolites generated by the transduced cells revealed in addition to PGI2 a significant quantity of PGE2 and a small amount of 12-hydroxy-5,8, I0-heptadecatrienoic acid (HHT). Since PGE2 and HHT are derived from PGH2, we interpret the results to indicate that overexpression of PGHS-1 leads to the synthesis of a large quantity of PGH2 which exceeds the capacity of PGI synthase and the excess PGH2 is converted to PGE2 and HHT by enzymatic and nonenzymatic mechanisms. The PGI synthase step, hence, represents the final bottleneck for controlling the synthesis of PGI2. To enhance PGO2 synthesis optimally at the vascular injury sites for defending against thrombus formation, enhanced expression of PGI synthase in conjunction with enhanced PGHS may be needed. The HPLC analysis also showed that the quantity of free AA in PGHS-1-enhanced cells was approximately equivalent to that in control cells despite a major difference in the AA metabolic activity between PGHS( R) and control cells. The reason for the release of a similar level of free AA irrespective to the state ofAA metabolism is unclear (Fig. 4) . It may be speculated that cells possess a mechanism for allowing the release ofonly a small amount ofunmetabolized AA. It is interesting to note that the basal level of PGI2 production was at least an order of magnitude higher than the basal level produced by EA.926 cells or human umbilical vein endothelial cells. This implies that even at the quiescent state, phospholipases in this transduced cell line were highly activated, thereby releasing arachidonic acid which was converted to PGI2 via the PGHS pathway. The mechanism by which this occurs requires further investigation.
Little is known about the use of SV40 late promoter region for increasing mammalian gene expression. In this study, we demonstrate that it enhances PGHS-1 expression significantly and when compared to retroviral LTR promoter activity, its strength in enhancing PGHS-1 mRNA is -50% of LTR promoter activity. Two transcription start sites were identified in our construct. Ghosh et al. reported multiple potential transcription start sites in SV40 late promoter region (32) . Sequence comparison indicates that the transcription sites in our construct are different from the potential sites reported by Ghosh et al. (32) . This may be due to a deletion of 17 bp in the sequence reported by Ghosh et al. (between nucleotide residues 95 and 96) when compared to the sequence reported in GenBank and reported by Fromm and Berg (33) . When these missing base pairs are taken into consideration, the two transcription start sites noted in our study coincide with two major start sites reported by Ghosh et al. (32) . These results indicate that the promoter activity is upstream from these two start sites. This cell line may be useful for further characterizing the SV40 late promoter activities.
